Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy

Detalhes bibliográficos
Autor(a) principal: Costa, Bianca
Data de Publicação: 2022
Outros Autores: Corrêa, Luana Barbosa, Silva, Patrícia Machado Rodrigues e, Sá, Yago Amigo Pinho Jannini de, Guimarães, Fernanda Verdini, Alencar, Luciana Magalhães Rebelo, Simões, Rafael Loureiro, Helal Neto, Edward, Ricci Junior, Eduardo, Henriques, Maria das Graças Muller de Oliveira, Rosas, Elaine Cruz, Oliveira, Ralph Santos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/50942
Resumo: Comissão Brasileira de Energia Nuclear. Instituto de Engenharia Nuclear. Laboratório de Nanorradiofármacos e Síntese de Novos Radiofármacos.. Rio de Janeiro, RJ, Brasil.
id CRUZ_f6e0566ef822287396e4059eb1202a7d
oai_identifier_str oai:www.arca.fiocruz.br:icict/50942
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Costa, BiancaCorrêa, Luana BarbosaSilva, Patrícia Machado Rodrigues eSá, Yago Amigo Pinho Jannini deGuimarães, Fernanda VerdiniAlencar, Luciana Magalhães RebeloSimões, Rafael LoureiroHelal Neto, EdwardRicci Junior, EduardoHenriques, Maria das Graças Muller de OliveiraRosas, Elaine CruzOliveira, Ralph Santos2022-01-29T14:43:37Z2022-01-29T14:43:37Z2022COSTA. BIanca et al. Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy. Food Hydrocolloids for Heath. v. 2, 100049, p. 1 - 7, Oct. 2022.2667-0259https://www.arca.fiocruz.br/handle/icict/5094210.1016/j.fhfh.2021.100049engElsevier B. V.TerapiaInflamaçãoTerapia com radionuclídeosRadiofarmáciaInflammationTherapyRadionuclide therapyRadiopharmacyUsing pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapyinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleComissão Brasileira de Energia Nuclear. Instituto de Engenharia Nuclear. Laboratório de Nanorradiofármacos e Síntese de Novos Radiofármacos.. Rio de Janeiro, RJ, Brasil.Comissão Brasileira de Energia Nuclear. Instituto de Engenharia Nuclear. Laboratório de Nanorradiofármacos e Síntese de Novos Radiofármacos.. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Farmanguinhos. Laboratório de Farmacologia Aplicada. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Inflamação. Rio de Janeiro, RJ, Brasil.Universidade Federal do Maranhão. Laboratório de Biofísica e Nanossistemas. São Luis, MA, Brasil.Comissão Brasileira de Energia Nuclear. Instituto de Engenharia Nuclear. Laboratório de Nanorradiofármacos e Síntese de Novos Radiofármacos.. Rio de Janeiro, RJ, Brasil.Comissão Brasileira de Energia Nuclear. Instituto de Engenharia Nuclear. Laboratório de Nanorradiofármacos e Síntese de Novos Radiofármacos.. Rio de Janeiro, RJ, Brasil.Universidade Federal do Rio de Janeiro. Faculdade de Farmácia. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Farmanguinhos. Laboratório de Farmacologia Aplicada. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Farmanguinhos. Laboratório de Farmacologia Aplicada. Rio de Janeiro, RJ, BrasilComissão Brasileira de Energia Nuclear. Instituto de Engenharia Nuclear. Laboratório de Nanorradiofármacos e Síntese de Novos Radiofármacos.. Rio de Janeiro, RJ, Brasil / Universidade Estadual da Zona Oeste. Laboratório de Radiofarmácia e Nanorradiofármacos. Rio de Janeiro, RJ, Brasil.Inflammation is a phenomenon responsible for the perturbation of homeostasis in several levels, with many sources, such as infection, injury, and exposure to contaminants. The necessity of new products that are effective in treating inflammation processes as can selectively imaging an inflammation site is a global issue. In this study, we have evaluated the applicability of Fucoidan as a therapeutic and imaging agent. We have assessed the Fucoidan in two inflammation models for therapeutic purposes: arthritis and lungs (LPS). In the case of use as an imaging agent, we evaluated the radiolabeled Fucoidan with 99mTc in inflamed lungs (LPS). The results demonstrated that Fucoidan has a therapeutic anti-inflammatory effect, especially in the lung model (LPS). Additionally, the imaging application demonstrated that radiolabeled Fucoidan (99mTc-Fucoidan) has an important chemoattraction for inflammation sites with very high bioaccumulation, which permits to think in an imaging application.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/50942/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALYagoAmigoPinho_Sá_etal_IOC_2021.pdfYagoAmigoPinho_Sá_etal_IOC_2021.pdfapplication/pdf818462https://www.arca.fiocruz.br/bitstream/icict/50942/2/YagoAmigoPinho_S%c3%a1_etal_IOC_2021.pdfa21483cf45fd3c613b3c6badfc1cf7b8MD52icict/509422022-01-29 11:43:37.277oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352022-01-29T14:43:37Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy
title Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy
spellingShingle Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy
Costa, Bianca
Terapia
Inflamação
Terapia com radionuclídeos
Radiofarmácia
Inflammation
Therapy
Radionuclide therapy
Radiopharmacy
title_short Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy
title_full Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy
title_fullStr Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy
title_full_unstemmed Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy
title_sort Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy
author Costa, Bianca
author_facet Costa, Bianca
Corrêa, Luana Barbosa
Silva, Patrícia Machado Rodrigues e
Sá, Yago Amigo Pinho Jannini de
Guimarães, Fernanda Verdini
Alencar, Luciana Magalhães Rebelo
Simões, Rafael Loureiro
Helal Neto, Edward
Ricci Junior, Eduardo
Henriques, Maria das Graças Muller de Oliveira
Rosas, Elaine Cruz
Oliveira, Ralph Santos
author_role author
author2 Corrêa, Luana Barbosa
Silva, Patrícia Machado Rodrigues e
Sá, Yago Amigo Pinho Jannini de
Guimarães, Fernanda Verdini
Alencar, Luciana Magalhães Rebelo
Simões, Rafael Loureiro
Helal Neto, Edward
Ricci Junior, Eduardo
Henriques, Maria das Graças Muller de Oliveira
Rosas, Elaine Cruz
Oliveira, Ralph Santos
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Costa, Bianca
Corrêa, Luana Barbosa
Silva, Patrícia Machado Rodrigues e
Sá, Yago Amigo Pinho Jannini de
Guimarães, Fernanda Verdini
Alencar, Luciana Magalhães Rebelo
Simões, Rafael Loureiro
Helal Neto, Edward
Ricci Junior, Eduardo
Henriques, Maria das Graças Muller de Oliveira
Rosas, Elaine Cruz
Oliveira, Ralph Santos
dc.subject.other.pt_BR.fl_str_mv Terapia
Inflamação
Terapia com radionuclídeos
Radiofarmácia
topic Terapia
Inflamação
Terapia com radionuclídeos
Radiofarmácia
Inflammation
Therapy
Radionuclide therapy
Radiopharmacy
dc.subject.en.pt_BR.fl_str_mv Inflammation
Therapy
Radionuclide therapy
Radiopharmacy
description Comissão Brasileira de Energia Nuclear. Instituto de Engenharia Nuclear. Laboratório de Nanorradiofármacos e Síntese de Novos Radiofármacos.. Rio de Janeiro, RJ, Brasil.
publishDate 2022
dc.date.accessioned.fl_str_mv 2022-01-29T14:43:37Z
dc.date.available.fl_str_mv 2022-01-29T14:43:37Z
dc.date.issued.fl_str_mv 2022
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv COSTA. BIanca et al. Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy. Food Hydrocolloids for Heath. v. 2, 100049, p. 1 - 7, Oct. 2022.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/50942
dc.identifier.issn.pt_BR.fl_str_mv 2667-0259
dc.identifier.doi.none.fl_str_mv 10.1016/j.fhfh.2021.100049
identifier_str_mv COSTA. BIanca et al. Using pure Fucoidan and radiolabeled Fucoidan (99mTc-Fucoidan) as a new agent for inflammation diagnosis and therapy. Food Hydrocolloids for Heath. v. 2, 100049, p. 1 - 7, Oct. 2022.
2667-0259
10.1016/j.fhfh.2021.100049
url https://www.arca.fiocruz.br/handle/icict/50942
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier B. V.
publisher.none.fl_str_mv Elsevier B. V.
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/50942/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/50942/2/YagoAmigoPinho_S%c3%a1_etal_IOC_2021.pdf
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
a21483cf45fd3c613b3c6badfc1cf7b8
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009260369412096

Registros relacionados